Drug Profile
Granisetron transdermal - Kyowa Kirin International
Alternative Names: Sancuso; SP 01; SP-01 - Solasia PharmaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator ProStrakan
- Developer Kyowa Kirin; Kyowa Kirin International; LG Chem; NewBridge Pharmaceuticals; Solasia Pharma
- Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chemotherapy-induced nausea and vomiting
Most Recent Events
- 25 Feb 2023 Cumberland Pharmaceuticals terminates national co-promotion agreement with Verity Pharmaceuticals to support granisetron transdermal in the US
- 09 May 2022 Cumberland Pharmaceuticals and Verity Pharmaceuticals agree to co-promote Granisetron transdermal in USA for Chemotherapy-induced nausea and vomiting
- 07 Mar 2022 Cumberland Pharmaceuticals owns patent for granisetron transdermal in USA